Quick Answer
Arbutus Biopharma Corp reported Cash And Cash Equivalents At Carrying Value of $18.01 million for the year ending 2025.
- Arbutus Biopharma Corp showed a decrease of -50.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Arbutus Biopharma Corp's annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), Arbutus Biopharma Corp's Cash And Cash Equivalents At Carrying Value has declined by 31.3%.
- Historical annual values: Fiscal year 2025: $18.01 million | Fiscal year 2024: $36.33 million | Fiscal year 2023: $26.29 million | Fiscal year 2022: $30.78 million | Fiscal year 2021: $109.28 million | Fiscal year 2020: $52.25 million | Fiscal year 2019: $31.80 million | Fiscal year 2018: $36.94 million | Fiscal year 2017: $54.29 million | Fiscal year 2016: $23.41 million | Fiscal year 2015: $166.78 million | Fiscal year 2014: $72.19 million | Fiscal year 2013: $68.72 million | Fiscal year 2012: $47.02 million | Fiscal year 2011: $9.03 million | Fiscal year 2010: $12.41 million | Fiscal year 2009: $24.40 million | Fiscal year 2008: $26.22 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: